PD24: Kidney Cancer: Advanced (including Drug Therapy) II

Podium Session Moderator(s)

• 

  Stephen Boorjian, Dr.

  Professor and Chair, Department of Urology
  Mayo Clinic
• AL

  Alessandro Larcher, MD
• 

  Michael Whalen, MD

  George Washington University School of Medicine & Health Science

Presentations:

• 7:00 AM – 7:10 AM CST

  PD24-01: The Selection for CytoREductivE Nephrectomy (SCREEN) Score: Surgical Risk Stratification Integrating Radiographic Features
  

  Podium Presenter: Daniel Shapiro, MD (he/him/his)
• 7:10 AM – 7:20 AM CST

  PD24-02: Impact of systemic therapy (ST) on deferred cytoreductive nephrectomy (CN) perioperative outcomes: A National Surgical Quality Improvement Program (NSQIP) analysis
  

  Podium Presenter: Shawn Dason
• 7:20 AM – 7:30 AM CST

  PD24-03: Best Treatment For Oligometastatic Renal Cancer: A Quasi-Individual Patient Data Analysis
  

  Podium Presenter: Giuseppe Fallara, MD
• 7:30 AM – 7:40 AM CST

  PD24-04: Outcomes of Deferred Cytoreductive Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis
  

  Podium Presenter: Kevin Hakimi, BS – University of California San Diego
• 7:40 AM – 7:50 AM CST

  PD24-05: Complete Pathological Response in Patients Undergoing Nephrectomy for Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Therapy: A Multicenter Study
  

  Podium Presenter: Alireza Ghoreifi, MD (he/him/his) – USC
• 7:50 AM – 8:00 AM CST

  PD24-06: Assessment of Surgical Complications in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Receiving Perioperative Cabozantinib and Nivolumab on Cyto-KIK Clinical Trial
  

  Podium Presenter: Eric A. Singer, MD, MA, FACS
• 8:00 AM – 8:10 AM CST

  PD24-07: First Analysis of the Safety and Efficacy of UGN-101 in the Treatment of Ureteral Tumors
  

  Podium Presenter: Joseph M. Jacob
• 8:10 AM – 8:20 AM CST

  PD24-08: Sequential usage of mTOR inhibitor followed by immunotherapies for cabozantinib-resistant metastatic clear cell renal cell carcinomas
  

  Podium Presenter: Jee Soo Soo Park, MD,PhD
• 8:20 AM – 8:30 AM CST

  PD24-09: Phase II, Multi-center Study of Sintilimab in Combination with Axitinib in Patients with Advanced Fumarate Hydratase-deficient Renal Cell Carcinoma
  

  Podium Presenter: Xingming Zhang
• 8:30 AM – 8:40 AM CST

  PD24-10: An Integrative Analysis of Age-Dependent Genetic Aberrations Associated with Renal Cell Cancer
  

  Podium Presenter: Mohammed Al-Toubat
• 8:40 AM – 8:50 AM CST

  PD24-11: Hot clear cell renal cell carcinoma immune status: illusion or reality?
  

  Podium Presenter: Yi Lu
• 8:50 AM – 9:00 AM CST

  PD24-12: Association between antibiotic therapy and treatment efficacy in renal cell carcinoma patients receiving either immune checkpoint inhibitors or tyrosine kinase inhibitors
  

  Podium Presenter: Avery Braun